Publications

Adoptive T-cell therapy for Hodgkin lymphoma.

Ho C, Ruella M, Levine BL, Svoboda J. Adoptive T-cell therapy for Hodgkin lymphoma. Blood Adv. 2021 Oct 26;5(20):4291-4302. doi: 10.1182/bloodadvances.2021005304. PMID: 34610100.

 

Overcoming Intrinsic Resistance of Cancer Cells to CAR T-Cell Killing.

Lemoine J, Ruella M, Houot R. Overcoming Intrinsic Resistance of Cancer Cells to CAR T-Cell Killing. Clin Cancer Res. 2021 Jul 12. doi: 10.1158/1078-0432.CCR-21-1559. Epub ahead of print. PMID: 34253582.

 

Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy.

Chong EA, Ruella M, Schuster SJ; Lymphoma Program Investigators at the University of Pennsylvania. Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy. N Engl J Med. 2021 Feb 18;384(7):673-674. doi: 10.1056/NEJMc2030164. PMID: 33596362.
 

Strategy to prevent epitope masking in CAR.CD19+ B-cell leukemia blasts.

Quintarelli C, Guercio M, Manni S, Boffa I, Sinibaldi M, Di Cecca S, Caruso S, Abbaszadeh Z, Camera A, Cembrola B, Ciccone R, Orfao A, Martin-Martin L, Gutierrez-Herrero S, Herrero-Garcia M, Cazzaniga G, Nunes V, Songia S, Marcatili P, Marin FI, Ruella M, Bertaina V, Vinti L, Del Bufalo F, Algeri M, Merli P, De Angelis B, Locatelli F. Strategy to prevent epitope masking in CAR.CD19+ B-cell leukemia blasts. J Immunother Cancer. 2021 Jun;9(6):e001514. doi: 10.1136/jitc-2020-001514. PMID: 34135100; PMCID: PMC8211055.

 

Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells.

Singh N, Frey NV, Engels B, Barrett DM, Shestova O, Ravikumar P, Cummins KD, Lee YG, Pajarillo R, Chun I, Shyu A, Highfill SL, Price A, Zhao L, Peng L, Granda B, Ramones M, Lu XM, Christian DA, Perazzelli J, Lacey SF, Roy NH, Burkhardt JK, Colomb F, Damra M, Abdel-Mohsen M, Liu T, Liu D, Standley DM, Young RM, Brogdon JL, Grupp SA, June CH, Maude SL, Gill S, Ruella M. Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells. Nat Med. 2021 May;27(5):842-850. doi: 10.1038/s41591-021-01326-5. Epub 2021 Apr 22. PMID: 33888899; PMCID: PMC8451032.

 

Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy.

Chong EA, Alanio C, Svoboda J, Nasta SD, Landsburg DJ, Lacey SF, Ruella M, Bhattacharyya S, Wherry EJ, Schuster SJ. Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy. Blood. 2021 Sep 9:blood.2021012634. doi: 10.1182/blood.2021012634. Epub ahead of print. PMID: 34496014.

 

18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Following Chimeric Antigen Receptor T-cell Therapy in Large B-cell Lymphoma.

Ruff A, Ballard HJ, Pantel AR, Namoglu EC, Hughes ME, Nasta SD, Chong EA, Bagg A, Ruella M, Farwell MD, Svoboda J, Sellmyer MA. 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Following Chimeric Antigen Receptor T-cell Therapy in Large B-cell Lymphoma. Mol Imaging Biol. 2021 Jul 6. doi: 10.1007/s11307-021-01627-8. Epub ahead of print. PMID: 34231105.

 

The current landscape of single-cell transcriptomics for cancer immunotherapy

Guruprasad P, Lee Y.G., Kim K.H. and Ruella M. The Current Landscape of Single-Cell Transcriptomics for Cancer Immunotherapy. J Exp Med. 2021 Jan 4;218(1):e20201574. doi: 10.1084/jem.20201574. PMID: 33601414; PMCID: PMC7754680.

 

Immunogenicity of CAR T cells in cancer therapy

Wagner DL, Fritsche E, Pulsipher MA, Ahmed N, Hamieh M, Hegde M, Ruella M, Savoldo B, Shah NN, Turtle CJ, Wayne AS, Abou-El-Enein M. Immunogenicity of CAR T cells in cancer therapy. Nat Rev Clin Oncol. 2021 Feb 25. doi: 10.1038/s41571-021-00476-2. Epub ahead of print. PMID: 33633361.

 

CAR-T TREK through the lymphoma universe, to boldly go where no other therapy has gone before

Ghilardi G, Braendstrup P, Chong EA, Schuster SJ, Svoboda J, Ruella M. CAR-T TREK through the lymphoma universe, to boldly go where no other therapy has gone before. Br J Haematol. 2021 May;193(3):449-465. doi: 10.1111/bjh.17191. Epub 2020 Nov 21. PMID: 33222167.

 

Acute Kidney Injury Following Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma in a Kidney Transplant Recipient.

Melilli E, Mussetti A, Linares GS, Ruella M, La Salette C, Savchenko A, Taco MDR, Montero N, Grinyo J, Fava A, Gomà M, Meneghini M, Manonelles A, Cruzado J, Sureda A, Bestard O. Acute Kidney Injury Following Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma in a Kidney Transplant Recipient. Kidney Med. 2021 May 28;3(4):665-668. doi: 10.1016/j.xkme.2021.03.011. PMID: 34401733; PMCID: PMC8350835.

 

The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice.

Cerrano M, Ruella M, Perales MA, Vitale C, Faraci DG, Giaccone L, Coscia M, Maloy M, Sanchez-Escamilla M, Elsabah H, Fadul A, Maffini E, Pittari G, Bruno B. Front Immunol. 2020 May 12;11:888. doi: 10.3389/fimmu.2020.00888. eCollection 2020.PMID: 32477359 Free PMC article. Review.

 

Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas.

Svoboda J, Bair SM, Landsburg DJ, Nasta SD, Nagle SJ, Barta SK, Khan N, Filicko-O'Hara J, Gaballa S, Strelec L, Chong E, Mitnick S, Waite TS, King C, Ballard H, Youngman M, Gerson J, Plastaras JP, Maity A, Bogusz AM, Hung SS, Nakamura H, Nejati R, Steidl C, Lim M, Ruella M, Schuster SJ.Haematologica. 2020 May 15:haematol.2019.238675. doi: 10.3324/haematol.2019.238675. Online ahead of print.PMID: 32414850 Free article.

 

Human chimeric antigen receptor macrophages for cancer immunotherapy.

Klichinsky M, Ruella M, Shestova O, Lu XM, Best A, Zeeman M, Schmierer M, Gabrusiewicz K, Anderson NR, Petty NE, Cummins KD, Shen F, Shan X, Veliz K, Blouch K, Yashiro-Ohtani Y, Kenderian SS, Kim MY, O'Connor RS, Wallace SR, Kozlowski MS, Marchione DM, Shestov M, Garcia BA, June CH, Gill S.Nat Biotechnol. 2020 Mar 23. doi: 10.1038/s41587-020-0462-y. Online ahead of print.PMID: 32361713

 

Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell Dysfunction.

Singh N, Lee YG, Shestova O, Ravikumar P, Hayer KE, Hong SJ, Lu XM, Pajarillo R, Agarwal S, Kuramitsu S, Orlando EJ, Mueller KT, Good CR, Berger SL, Shalem O, Weitzman MD, Frey NV, Maude SL, Grupp SA, June CH, Gill S, Ruella M.Cancer Discov. 2020 Apr;10(4):552-567. doi: 10.1158/2159-8290.CD-19-0813. Epub 2020 Jan 30.PMID: 32001516

 

The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19.

Braendstrup P, Levine BL, Ruella M.Cytotherapy. 2020 Feb;22(2):57-69. doi: 10.1016/j.jcyt.2019.12.004. Epub 2020 Feb 1.PMID: 32014447 Review.

 

A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor-positive cells.

Ruella M, Barrett DM, Shestova O, Perazzelli J, Posey AD, Hong SJ, Kozlowski M, Lacey SF, Melenhorst JJ, June CH, Gill SI.Blood. 2020 Feb 13;135(7):505-509. doi: 10.1182/blood.2019001859.PMID: 31703119 Free PMC article.

 

Beat pediatric ALL MRD: CD28 CAR T and transplant.

Ruella M, Locke FL.Blood. 2019 Dec 26;134(26):2333-2335. doi: 10.1182/blood.2019003821.PMID: 31877213 Free PMC article.

 

Dynamic Changes in Gene Mutational Landscape With Preservation of Core Mutations in Mantle Cell Lymphoma Cells.

Zhang Q, Wang HY, Liu X, Roth MH, Shestov AA, Lee SC, Jain K, Soderquist C, Xiong QB, Ruella M, Strauser H, Glickson JD, Schuster SJ, Ptasznik A, Wasik MA.Front Oncol. 2019 Jul 3;9:568. doi: 10.3389/fonc.2019.00568. eCollection 2019.PMID: 31334109 Free PMC article.

 

Influence of Donor and Recipient Gender on Telomere Maintenance after Umbilical Cord Blood Cell Transplantation: A Study by the Gruppo Italiano Trapianto Di Midollo Osseo.

Derenzini E, Risso A, Ruella M, Spatola T, Milone G, Pioltelli P, Iori AP, Santarone S, Bosi A, Rambaldi A, Bacigalupo AP, Arcese W, Tarella C.Biol Blood Marrow Transplant. 2019 Jul;25(7):1387-1394. doi: 10.1016/j.bbmt.2019.03.026. Epub 2019 Mar 30.PMID: 30935966

 

Emerging Cellular Therapies for Cancer.

Guedan S, Ruella M, June CH.Annu Rev Immunol. 2019 Apr 26;37:145-171. doi: 10.1146/annurev-immunol-042718-041407. Epub 2018 Dec 10.PMID: 30526160 Review.

 

Novel Immunotherapies for T Cell Lymphoma and Leukemia.

Ghione P, Moskowitz AJ, De Paola NEK, Horwitz SM, Ruella M.Curr Hematol Malig Rep. 2018 Dec;13(6):494-506. doi: 10.1007/s11899-018-0480-8.PMID: 30317410 Free PMC article. Review.

 

Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell.

Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, Klichinsky M, Shestova O, Patel PR, Kulikovskaya I, Nazimuddin F, Bhoj VG, Orlando EJ, Fry TJ, Bitter H, Maude SL, Levine BL, Nobles CL, Bushman FD, Young RM, Scholler J, Gill SI, June CH, Grupp SA, Lacey SF, Melenhorst JJ.Nat Med. 2018 Oct;24(10):1499-1503. doi: 10.1038/s41591-018-0201-9. Epub 2018 Oct 1.PMID: 30275568 Free PMC article.

 

Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy).

Ascierto PA, Brugarolas J, Buonaguro L, Butterfield LH, Carbone D, Daniele B, Ferris R, Fox BA, Galon J, Gridelli C, Kaufman HL, Klebanoff CA, Melero I, Nathan P, Paulos CM, Ruella M, Sullivan R, Zarour H, Puzanov I.J Immunother Cancer. 2018 Jul 11;6(1):69. doi: 10.1186/s40425-018-0377-z.PMID: 29996914 Free PMC article. Review.

 

Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma.

Bu DX, Singh R, Choi EE, Ruella M, Nunez-Cruz S, Mansfield KG, Bennett P, Barton N, Wu Q, Zhang J, Wang Y, Wei L, Cogan S, Ezell T, Joshi S, Latimer KJ, Granda B, Tschantz WR, Young RM, Huet HA, Richardson CJ, Milone MC.Oncotarget. 2018 May 25;9(40):25764-25780. doi: 10.18632/oncotarget.25359. eCollection 2018 May 25.PMID: 29899820 Free PMC article.

 

Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia.

Kim MY, Yu KR, Kenderian SS, Ruella M, Chen S, Shin TH, Aljanahi AA, Schreeder D, Klichinsky M, Shestova O, Kozlowski MS, Cummins KD, Shan X, Shestov M, Bagg A, Morrissette JJD, Sekhri P, Lazzarotto CR, Calvo KR, Kuhns DB, Donahue RE, Behbehani GK, Tsai SQ, Dunbar CE, Gill S.Cell. 2018 May 31;173(6):1439-1453.e19. doi: 10.1016/j.cell.2018.05.013. Epub 2018 May 31.PMID: 29856956 Free PMC article.

 

Predicting Dangerous Rides in CAR T Cells: Bridging the Gap between Mice and Humans.

Ruella M, June CH.Mol Ther. 2018 Jun 6;26(6):1401-1403. doi: 10.1016/j.ymthe.2018.05.005. Epub 2018 May 19.PMID: 29784587 Free PMC article. No abstract available.

 

Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.

Watanabe K, Luo Y, Da T, Guedan S, Ruella M, Scholler J, Keith B, Young RM, Engels B, Sorsa S, Siurala M, Havunen R, Tähtinen S, Hemminki A, June CH.JCI Insight. 2018 Apr 5;3(7):e99573. doi: 10.1172/jci.insight.99573. eCollection 2018 Apr 5.PMID: 29618658 Free PMC article.

 

lding upon the success of CART19: chimeric antigen receptor T cells for hematologic malignancies.

Rotolo A, Karadimitris A, Ruella M.Leuk Lymphoma. 2018 Sep;59(9):2040-2055. doi: 10.1080/10428194.2017.1403024. Epub 2017 Nov 22.PMID: 29165008 Free PMC article. Review.

 

Next-Generation Chimeric Antigen Receptor T-Cell Therapy: Going off the Shelf.

Ruella M, Kenderian SS.BioDrugs. 2017 Dec;31(6):473-481. doi: 10.1007/s40259-017-0247-0.PMID: 29143249 Free PMC article. Review.

 

Genome-Editing Technologies in Adoptive T Cell Immunotherapy for Cancer.

Singh N, Shi J, June CH, Ruella M.Curr Hematol Malig Rep. 2017 Dec;12(6):522-529. doi: 10.1007/s11899-017-0417-7.PMID: 29039115 Free PMC article. Review.

 

Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells.

Ruella M, Klichinsky M, Kenderian SS, Shestova O, Ziober A, Kraft DO, Feldman M, Wasik MA, June CH, Gill S.Cancer Discov. 2017 Oct;7(10):1154-1167. doi: 10.1158/2159-8290.CD-16-0850. Epub 2017 Jun 2.PMID: 28576927 Free PMC article.

 

Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia.

Tasian SK, Kenderian SS, Shen F, Ruella M, Shestova O, Kozlowski M, Li Y, Schrank-Hacker A, Morrissette JJD, Carroll M, June CH, Grupp SA, Gill S.Blood. 2017 Apr 27;129(17):2395-2407. doi: 10.1182/blood-2016-08-736041. Epub 2017 Feb 28.PMID: 28246194 Free PMC article.

 

Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms.

Ruella M, Kenderian SS, Shestova O, Klichinsky M, Melenhorst JJ, Wasik MA, Lacey SF, June CH, Gill S.Leukemia. 2017 Jan;31(1):246-248. doi: 10.1038/leu.2016.262. Epub 2016 Sep 28.PMID: 27677739 No abstract available.

 

Walking a tightrope: clinical use of ibrutinib in mantle cell lymphoma in the elderly.

Ruella M, Soubeyran P.Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):432-436. doi: 10.1182/asheducation-2016.1.432.PMID: 27913512 Free PMC article. Review.

 

Gill S, Tasian SK, Ruella M, et al. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood. 2014;123(15):2343-2354.

Blood. 2016 Nov 24;128(21):2585. doi: 10.1182/blood-2016-10-745448.PMID: 27884838 Free PMC article. No abstract available.

 

Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies.

Ruella M, Maus MV.Comput Struct Biotechnol J. 2016 Sep 28;14:357-362. doi: 10.1016/j.csbj.2016.09.003. eCollection 2016.PMID: 27761200 Free PMC article. Review.

 

Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies.

Ruella M, Barrett DM, Kenderian SS, Shestova O, Hofmann TJ, Perazzelli J, Klichinsky M, Aikawa V, Nazimuddin F, Kozlowski M, Scholler J, Lacey SF, Melenhorst JJ, Morrissette JJ, Christian DA, Hunter CA, Kalos M, Porter DL, June CH, Grupp SA, Gill S.J Clin Invest. 2016 Oct 3;126(10):3814-3826. doi: 10.1172/JCI87366. Epub 2016 Aug 29.PMID: 27571406 Free PMC article.

 

Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You.

Ruella M, June CH.Curr Hematol Malig Rep. 2016 Oct;11(5):368-84. doi: 10.1007/s11899-016-0336-z.PMID: 27475429 Review.

 

Conservative treatment of tendinopathies of upper limbs in occupational health: a literature review

Sartorio F, Garzonio F, Vercelli S, Bravini E, Ruella C, Maglio R, Cisari C, Ferriero G.Med Lav. 2016 Mar 24;107(2):112-28.PMID: 27015027 Review. Italian.

 

Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study.

Ruella M, Filippi AR, Bruna R, Di Russo A, Magni M, Caracciolo D, Passera R, Matteucci P, Di Nicola M, Corradini P, Parvis G, Gini G, Olivieri A, Ladetto M, Ricardi U, Tarella C, Devizzi L.Int J Radiat Oncol Biol Phys. 2016 Mar 15;94(4):783-91. doi: 10.1016/j.ijrobp.2015.12.019. Epub 2015 Dec 17.PMID: 26972651 Clinical Trial.

 

Smart CARS: optimized development of a chimeric antigen receptor (CAR) T cell targeting epidermal growth factor receptor variant III (EGFRvIII) for glioblastoma.

Ruella M, Levine BL.Ann Transl Med. 2016 Jan;4(1):13. doi: 10.3978/j.issn.2305-5839.2015.10.11.PMID: 26855949 Free PMC article. No abstract available.

 

The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma.

Ruella M, Kenderian SS, Shestova O, Fraietta JA, Qayyum S, Zhang Q, Maus MV, Liu X, Nunez-Cruz S, Klichinsky M, Kawalekar OU, Milone M, Lacey SF, Mato A, Schuster SJ, Kalos M, June CH, Gill S, Wasik MA.Clin Cancer Res. 2016 Jun 1;22(11):2684-96. doi: 10.1158/1078-0432.CCR-15-1527. Epub 2016 Jan 27.PMID: 26819453 Free article.

 

Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.

Fraietta JA, Beckwith KA, Patel PR, Ruella M, Zheng Z, Barrett DM, Lacey SF, Melenhorst JJ, McGettigan SE, Cook DR, Zhang C, Xu J, Do P, Hulitt J, Kudchodkar SB, Cogdill AP, Gill S, Porter DL, Woyach JA, Long M, Johnson AJ, Maddocks K, Muthusamy N, Levine BL, June CH, Byrd JC, Maus MV.Blood. 2016 Mar 3;127(9):1117-27. doi: 10.1182/blood-2015-11-679134. Epub 2016 Jan 26.PMID: 26813675 Free PMC article. Clinical Trial.

 

Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy.

Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G, Sussman R, Lanauze C, Ruella M, Gazzara MR, Martinez NM, Harrington CT, Chung EY, Perazzelli J, Hofmann TJ, Maude SL, Raman P, Barrera A, Gill S, Lacey SF, Melenhorst JJ, Allman D, Jacoby E, Fry T, Mackall C, Barash Y, Lynch KW, Maris JM, Grupp SA, Thomas-Tikhonenko A.Cancer Discov. 2015 Dec;5(12):1282-95. doi: 10.1158/2159-8290.CD-15-1020. Epub 2015 Oct 29.PMID: 26516065 Free PMC article.

 

CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia.

Kenderian SS, Ruella M, Shestova O, Klichinsky M, Aikawa V, Morrissette JJ, Scholler J, Song D, Porter DL, Carroll M, June CH, Gill S.Leukemia. 2015 Aug;29(8):1637-47. doi: 10.1038/leu.2015.52. Epub 2015 Feb 27.PMID: 25721896 Free PMC article.

 

How to train your T cell: genetically engineered chimeric antigen receptor T cells versus bispecific T-cell engagers to target CD19 in B acute lymphoblastic leukemia.

Ruella M, Gill S.Expert Opin Biol Ther. 2015 Jun;15(6):761-6. doi: 10.1517/14712598.2015.1009888. Epub 2015 Feb 2.PMID: 25640460

 

Chimeric antigen receptor T-cell therapy to target hematologic malignancies.

Kenderian SS, Ruella M, Gill S, Kalos M.Cancer Res. 2014 Nov 15;74(22):6383-9. doi: 10.1158/0008-5472.CAN-14-1530. Epub 2014 Nov 4.PMID: 25371415 Free article.

 

Rate of primary refractory disease in B and T-cell non-Hodgkin's lymphoma: correlation with long-term survival.

Tarella C, Gueli A, Delaini F, Rossi A, Barbui AM, Gritti G, Boschini C, Caracciolo D, Bruna R, Ruella M, Gottardi D, Passera R, Rambaldi A.PLoS One. 2014 Sep 25;9(9):e106745. doi: 10.1371/journal.pone.0106745. eCollection 2014.PMID: 25255081 Free PMC article.

 

A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera.

Lussana F, Carobbio A, Randi ML, Elena C, Rumi E, Finazzi G, Bertozzi I, Pieri L, Ruggeri M, Palandri F, Polverelli N, Elli E, Tieghi A, Iurlo A, Ruella M, Cazzola M, Rambaldi A, Vannucchi AM, Barbui T.Br J Haematol. 2014 Nov;167(4):541-6. doi: 10.1111/bjh.13080. Epub 2014 Aug 16.PMID: 25130523 Clinical Trial.

 

Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells.

Gill S, Tasian SK, Ruella M, Shestova O, Li Y, Porter DL, Carroll M, Danet-Desnoyers G, Scholler J, Grupp SA, June CH, Kalos M.Blood. 2014 Apr 10;123(15):2343-54. doi: 10.1182/blood-2013-09-529537. Epub 2014 Mar 4.PMID: 24596416 Free PMC article.

 

Adoptive immunotherapy for cancer.

Ruella M, Kalos M.Immunol Rev. 2014 Jan;257(1):14-38. doi: 10.1111/imr.12136.PMID: 24329787 Review.

For full list of publications, please visit PubMed.